SFI
JNCE

Susquehanna Fundamental Investments’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Susquehanna Fundamental Investments’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$242K Buy
35,698
+9,500
+36% +$67.7K ﹤0.01% 1312
2021
Q4 		$219K Sell
26,198
-3,405
-12% -$28.1K 0.01% 1215
2021
Q3 		$220K Sell
29,603
-4,191
-12% -$26K ﹤0.01% 1514
2021
Q2 		$230K Buy
+33,794
New +$281K ﹤0.01% 1445

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Susquehanna Fundamental Investments's JNCE Position: Q1 2022 in Review

Susquehanna Fundamental Investments increased its Jounce Therapeutics, Inc. Common Stock (JNCE) stake by 36% in Q1 2022, buying an estimated $67.7K and bringing the position to 35,698 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #1312.

Susquehanna Fundamental Investments first reported a position in JNCE in Q2 2021 and has held it in 4 quarters since. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • Susquehanna Fundamental Investments held 35,698 shares of Jounce Therapeutics, Inc. Common Stock worth $242K as of Q1 2022.
  • Susquehanna Fundamental Investments bought 9,500 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $67.7K.
  • Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1312 holding.
  • Susquehanna Fundamental Investments first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2021 and has held it in 4 quarters since.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.